<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We evaluated pre- and post-thymoquinone (TQ) treatment on 1,2-dimethyl-<z:chebi fb="0" ids="15571">hydrazine</z:chebi> (DMH)-induced <z:mp ids='MP_0003674'>oxidative stress</z:mp> during initiation and promotion of colon <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Wistar rats were induced with DMH (20mg/kg) for 10 or 20weeks, and treated with TQ (5mg/kg) </plain></SENT>
<SENT sid="2" pm="."><plain>Following sacrifice, the colons were analysed for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> development, reactive oxygen species (ROS) generation, <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation [conjugated diene (CD) and malondialdehyde (<z:chebi fb="14" ids="32506">MDA</z:chebi>)], <z:chebi fb="11" ids="22586">antioxidants</z:chebi> [<z:chebi fb="0" ids="16856">glutathione</z:chebi> peroxidase (GPx), catalase (CAT), <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase (SOD) and reduced <z:chebi fb="0" ids="16856">glutathione</z:chebi> (GSH)], and histological changes </plain></SENT>
<SENT sid="3" pm="."><plain>Increased ROS levels and <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation were seen during <z:e sem="disease" ids="C0598935" disease_type="Neoplastic Process" abbrv="">tumour initiation</z:e> and promotion </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> ROS-scavenging enzyme activities were increased upon shorter DMH treatment but not following longer treatment, while GSH amount was increased upon both treatments </plain></SENT>
<SENT sid="5" pm="."><plain>Oxidative state perturbations were associated with moderate <z:mp ids='MP_0000495'>colon dysplasia</z:mp> and 30% <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> incidence at initiation and marked <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and 100% <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> incidence at promotion </plain></SENT>
<SENT sid="6" pm="."><plain>TQ pre-treatment restored completely DMH-induced <z:mp ids='MP_0003674'>oxidative stress</z:mp> at initiation and established histological changes and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> development </plain></SENT>
<SENT sid="7" pm="."><plain>It also abrogated oxidative status aggravation at promotion, and significantly reduced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> incidence (67%) </plain></SENT>
<SENT sid="8" pm="."><plain>By comparison, TQ post-treatment corrected oxidative status and attenuated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> development at initiation </plain></SENT>
<SENT sid="9" pm="."><plain>It slightly reduced <z:chebi fb="14" ids="32506">MDA</z:chebi> and <z:chebi fb="11" ids="22586">antioxidant</z:chebi> level at promotion, with a slight reduction in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> state and <z:mpath ids='MPATH_589'>dysplasia</z:mpath> degree </plain></SENT>
<SENT sid="10" pm="."><plain>TQ is efficacious in protecting and curing DMH-induced initiation phase of <z:hpo ids='HP_0003003'>colon cancer</z:hpo>, while exerting a protective role at promotion </plain></SENT>
<SENT sid="11" pm="."><plain>TQ effect seems to be related to its capacity in preventing DMH-induced <z:mp ids='MP_0003674'>oxidative stress</z:mp> </plain></SENT>
<SENT sid="12" pm="."><plain>These in vivo results support the notion that TQ may be of value as a chemo-preventive alternative in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
</text></document>